S&P 500   4,538.43
DOW   34,580.08
QQQ   383.13
S&P 500   4,538.43
DOW   34,580.08
QQQ   383.13
S&P 500   4,538.43
DOW   34,580.08
QQQ   383.13
S&P 500   4,538.43
DOW   34,580.08
QQQ   383.13
NASDAQ:MRNS

Marinus Pharmaceuticals Stock Forecast, Price & News

$9.31
-1.01 (-9.79%)
(As of 12/3/2021 04:00 PM ET)
Add
Compare
Today's Range
$9.27
$10.41
50-Day Range
$9.31
$12.81
52-Week Range
$9.27
$20.04
Volume
187,629 shs
Average Volume
127,568 shs
Market Capitalization
$342.33 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
1.16
30 days | 90 days | 365 days | Advanced Chart
Receive MRNS News and Ratings via Email

Sign-up to receive the latest news and ratings for Marinus Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.


Marinus Pharmaceuticals logo

About Marinus Pharmaceuticals

Marinus Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the identification and development of neuropsychiatric therapeutics. Its clinical stage drug product candidate, ganaxolone, is a positive allosteric modulator being developed in three different dose forms: intravenous, capsule, and liquid. The company was founded by Geoffrey E. Chaiken, Harry H. Penner Jr., Vincent A. Pieribone and Kenneth R. Shaw on August 14, 2003 and is headquartered in Radnor, PA.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:MRNS
Employees
69
Year Founded
N/A

Sales & Book Value

Annual Sales
$1.72 million
Book Value
$2.02 per share

Profitability

Net Income
$-67.47 million
Net Margins
-572.12%
Pretax Margin
-572.12%

Debt

Price-To-Earnings

Miscellaneous

Free Float
35,479,000
Market Cap
$342.33 million
Optionable
Optionable

Company Calendar

Last Earnings
11/09/2021
Today
12/04/2021
Fiscal Year End
12/31/2021
Next Earnings (Estimated)
3/08/2022

MarketRank

Overall MarketRank

2.12 out of 5 stars

Medical Sector

485th out of 1,390 stocks

Pharmaceutical Preparations Industry

221st out of 668 stocks

Analyst Opinion: 3.5Community Rank: 4.8Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -












Marinus Pharmaceuticals (NASDAQ:MRNS) Frequently Asked Questions

Is Marinus Pharmaceuticals a buy right now?

7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Marinus Pharmaceuticals in the last year. There are currently 7 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Marinus Pharmaceuticals stock.
View analyst ratings for Marinus Pharmaceuticals
or view top-rated stocks.

How has Marinus Pharmaceuticals' stock been impacted by Coronavirus?

Marinus Pharmaceuticals' stock was trading at $6.56 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, MRNS shares have increased by 41.9% and is now trading at $9.31.
View which stocks have been most impacted by COVID-19
.

When is Marinus Pharmaceuticals' next earnings date?

Marinus Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Tuesday, March 8th 2022.
View our earnings forecast for Marinus Pharmaceuticals
.

How were Marinus Pharmaceuticals' earnings last quarter?

Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) posted its earnings results on Tuesday, November, 9th. The biopharmaceutical company reported ($0.53) EPS for the quarter, topping the consensus estimate of ($0.76) by $0.23. Marinus Pharmaceuticals had a negative trailing twelve-month return on equity of 86.10% and a negative net margin of 572.12%. During the same period in the previous year, the company posted ($0.51) earnings per share.
View Marinus Pharmaceuticals' earnings history
.

When did Marinus Pharmaceuticals' stock split? How did Marinus Pharmaceuticals' stock split work?

Marinus Pharmaceuticals shares reverse split before market open on Wednesday, September 23rd 2020. The 1-4 reverse split was announced on Tuesday, September 22nd 2020. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, September 22nd 2020. An investor that had 100 shares of Marinus Pharmaceuticals stock prior to the reverse split would have 25 shares after the split.

What price target have analysts set for MRNS?

7 equities research analysts have issued twelve-month price targets for Marinus Pharmaceuticals' shares. Their forecasts range from $23.00 to $40.00. On average, they expect Marinus Pharmaceuticals' share price to reach $34.60 in the next twelve months. This suggests a possible upside of 271.6% from the stock's current price.
View analysts' price targets for Marinus Pharmaceuticals
or view top-rated stocks among Wall Street analysts.

Who are Marinus Pharmaceuticals' key executives?

Marinus Pharmaceuticals' management team includes the following people:
  • Scott N. Braunstein, President, Chief Executive Officer & Director
  • Steven E. Pfanstiel, Chief Financial Officer & Treasurer
  • Joseph Hulihan, Chief Medical Officer
  • Martha E. Manning, Secretary, Vice President & General Counsel
  • Christy Shafer, Chief Commercial Officer

What other stocks do shareholders of Marinus Pharmaceuticals own?

What is Marinus Pharmaceuticals' stock symbol?

Marinus Pharmaceuticals trades on the NASDAQ under the ticker symbol "MRNS."

Who are Marinus Pharmaceuticals' major shareholders?

Marinus Pharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional investors include Lion Point Capital LP (9.88%), BlackRock Inc. (8.16%), Suvretta Capital Management LLC (5.98%), Geode Capital Management LLC (1.57%), Goldman Sachs Group Inc. (0.65%) and Kestra Private Wealth Services LLC (0.54%). Company insiders that own Marinus Pharmaceuticals stock include Edward F Smith and Scott Braunstein.
View institutional ownership trends for Marinus Pharmaceuticals
.

Which institutional investors are selling Marinus Pharmaceuticals stock?

MRNS stock was sold by a variety of institutional investors in the last quarter, including Two Sigma Advisers LP, Morgan Stanley, Dimensional Fund Advisors LP, Los Angeles Capital Management LLC, California State Teachers Retirement System, Jane Street Group LLC, BlackRock Inc., and New York State Common Retirement Fund.
View insider buying and selling activity for Marinus Pharmaceuticals
or view top insider-selling stocks.

Which institutional investors are buying Marinus Pharmaceuticals stock?

MRNS stock was purchased by a variety of institutional investors in the last quarter, including Suvretta Capital Management LLC, Kestra Private Wealth Services LLC, GSA Capital Partners LLP, SG Americas Securities LLC, Trexquant Investment LP, Bank of New York Mellon Corp, Citadel Advisors LLC, and Citigroup Inc..
View insider buying and selling activity for Marinus Pharmaceuticals
or or view top insider-buying stocks.

How do I buy shares of Marinus Pharmaceuticals?

Shares of MRNS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Marinus Pharmaceuticals' stock price today?

One share of MRNS stock can currently be purchased for approximately $9.31.

How much money does Marinus Pharmaceuticals make?

Marinus Pharmaceuticals has a market capitalization of $342.33 million and generates $1.72 million in revenue each year. The biopharmaceutical company earns $-67.47 million in net income (profit) each year or ($2.47) on an earnings per share basis.

How many employees does Marinus Pharmaceuticals have?

Marinus Pharmaceuticals employs 69 workers across the globe.

What is Marinus Pharmaceuticals' official website?

The official website for Marinus Pharmaceuticals is www.marinuspharma.com.

Where are Marinus Pharmaceuticals' headquarters?

Marinus Pharmaceuticals is headquartered at 100 Matsonford Rd Suite 500, Radnor PA, 19087.

How can I contact Marinus Pharmaceuticals?

Marinus Pharmaceuticals' mailing address is 100 Matsonford Rd Suite 500, Radnor PA, 19087. The biopharmaceutical company can be reached via phone at (484) 801-4670, via email at [email protected], or via fax at 203-315-0565.


This page was last updated on 12/4/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.